MyelinWatch EL
← Studies & programmes
Myelin repairStudy in peopleAccepting participants

SetPoint MS Pilot: testing an implanted nerve-stimulation device

Published by MyelinWatch:

Organisation
SetPoint Medical

SetPoint MS Pilot · The study tests a device that applies electrical pulses to the left vagus nerve, which carries signals between the brain and internal organs. It investigates whether changing nerve signals can influence immune activity and support myelin repair in relapsing-remitting MS. The device is implanted surgically under anaesthesia, while participants continue standard disease-modifying treatment.

What is being studied

The study tests a device that applies electrical pulses to the left vagus nerve, which carries signals between the brain and internal organs. It investigates whether changing nerve signals can influence immune activity and support myelin repair in relapsing-remitting MS. The device is implanted surgically under anaesthesia, while participants continue standard disease-modifying treatment.

Research stage

Study in people

The current listing is open to participants.

What we know so far

SetPoint Medical reported the first patients enrolled and implanted on 30 April 2026. The registry records an actual start on 17 April and, in its update posted on 2 September, lists the pilot as accepting participants with an estimated 60 participants. Assignment is random, with two participants allocated to active stimulation for every one allocated to a sham setting, in a blinded study. The main safety measure counts adverse events through week 96. Other exploratory measurements at week 48 include electrical responses in the visual pathway (VEP P100 latency) and a magnetic resonance imaging (MRI) measure of tissue properties called magnetisation transfer ratio (MTR). No results are posted. These measurements alone do not establish patient benefit or myelin repair.

What this means for patients today

Use for MS remains investigational and unapproved. Entering a study or receiving an implant does not show that it works. US approval for certain adults with rheumatoid arthritis concerns a different indication. The registry checked on 29 September lists nine US sites and none in Greece; participation still depends on eligibility and direct site contact. No established approved treatment in clinical practice has been proven to reliably restore myelin in MS.

Treatment or approach
Electrical stimulation of the vagus nerve alongside standard MS treatment
How it is intended to work
Uses a medical device to stimulate the vagus nerve
Where the study is running
Nine listed US sites; no Greek site listed in the registry checked on 29 September 2026
Source: ClinicalTrials.gov — official clinical-trial registry ↗Source: SetPoint Medical — official first-patients announcement, 30 April 2026 ↗
Published by MyelinWatch
Last substantive MyelinWatch update

Programme updates — newest research developments first

  1. Registered pilot study of a medical device in people; no results postedResearch event/source date:

    SetPoint reports first patients enrolled and implanted in its MS pilot study

    On 30 April 2026, SetPoint Medical announced that the first patients had enrolled and received implants in its pilot study for relapsing-remitting multiple sclerosis (MS). The device delivers electrical stimulation through an implant on the left vagus nerve, alongside continued standard disease-modifying treatment. The registry records the actual study start as 17 April 2026. In the registry update posted on 2 September 2026 and checked on 29 September, the study was accepting participants, with an estimated 60 participants and nine listed US sites. No results were posted. The April announcement is the event; the September dates refer to registry posting and verification.

    Source: SetPoint Medical — official company announcement ↗Source: ClinicalTrials.gov — NCT06796504; registry update posted 2 September 2026 ↗